Skip to content

An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction

Functional Magnetic Resonance Imaging Study to Explore the Mechanism and the Efficacy and Safety of Jianpi Yishen Huatan Granule for Cognitive Impairment After Acute Cerebral Infarction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02752867
Enrollment
40
Registered
2016-04-27
Start date
2016-12-31
Completion date
2019-11-30
Last updated
2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Keywords

traditional Chinese medicine granules, Cognitive Impairment, Acute cerebral infraction, treatment

Brief summary

The purpose of this study is to explore the pathogenesis of cognitive impairment after acute cerebral infarction by applying the multimodal function MRI to dynamically observe the changes of the value of NAA,Cho,Cr,FA in a certain region in the brain and the function of the brain ,and to provide a visual instrument for evaluating the therapeutical effects of Chinese medicine through the application of multimodal function MRI to observe the changes of the neurotransmitter in certain area in the brain before and after the treatment.

Detailed description

The present study is designed to assess the efficacy and safety of Jianpi Yishen Huatan granules with cognitive impairment after Acute Cerebral Infarction by fMRI and neuropsychology scales,as well as observe the symptoms,syndrome characteristics and neuropsychological changes of patients with cognitive dysfunction after acute cerebral infarction.And explore the pathogenesis of cognitive impairment after acute cerebral infarction by applying the multimodal function MRI to dynamically observe the changes of the value of NAA,Cho,Cr,FA in a certain region in the brain and the function of the brain ,and to provide a visual instrument for evaluating the therapeutical effects of Chinese medicine through the application of multimodal function MRI to observe the changes of the neurotransmitter in certain area in the brain before and after the treatment. The sample size is 40 of which 20 are from the intervention group and 20 are from the control group.

Interventions

DRUGJianpi Yishen Huatan Granules

Jianpi Yishen Huatan Granules contain Herba cistanche,Fructus Alpinia Oxyphyllae,Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one

Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients conform to the diagnostic criteria of acute ischemic stroke. * The cerebral infarction area lies in the blood supply area of middle cerebral artery: basal ganglia,corona radiate region or other subcortical regions.. * The cumulative infarction area is no more than 3.0 cm. * Stroke onset within 21 days * Age from forty to eighty, gender not limited * Neuropsychological assessments: Montreal Cognitive Assessment Scale scores less than 26 points or MMSE scores range from 19 points to 26 points in literates or MMSE scores range from 17 points to 24 points in illiterates * Informed and signed the informed consent

Exclusion criteria

* Transient Ischemic Attack * Stroke patients with the causes of cerebral hemorrhage, subarachnoid hemorrhage, brain tumors, brain injury, or blood diseases and so on. * Stroke with an onset of more than 21 days * Cerebral embolism caused by atrial fibrillation resulted from rheumatic heart disease, coronary heart disease and other heart diseases. * Patients who cannot cooperate with the check due to serious visual, hearing dysfunction, apraxia, aphasia. * Patients with other neurological diseases which can affect cognitive function (for example:Alzheimer's Disease,Parkinson's disease, frontotemporal dementia,Huntington's disease) * Patients with communication difficulties, or psychiatric disease * Depression (Hamilton Depression Scale scores more than or equal to 17 points) * Diagnosed with alcohol or drug dependence within the past six months * With other diseases which can cause cognitive dysfunction, Such as trauma,tumor or infection of the central nervous system, metabolic disorders, normal pressure hydrocephalus , folic acid or vitamin B12 Deficiency, thyroid hypofunction,sever anemia,sever Parkinson's Disease, encephalitis, syphilis or HIV * With a previous history of stroke and serious sequelae, and cannot cope with neuropsychological examination * With severe primary diseases, and cannot comply with the above scheme

Design outcomes

Primary

MeasureTime frameDescription
Verbal memory test(HVLT)90 daysUsing Verbal memory test(HVLT) to examine verbal memory
Mini-mental state examination(MMSE)90 daysMMSE is an acknowledged scale to measure cognition function from the aspects of orientation ability, memory, attention, calculation ability, recall and language,etc.
Digital color connection test (CCT)90 daysUsing Digital color connection test (CCT) to examine executive function and attention
Changes of the fMRI outcome after the treatment90 daysUsing the fMRI to measure the changes of neurotransmitter and brain function in the brain before and after the treatment.
Numerical sequence test(DS-S)90 daysUsing Numerical sequence test(DS-S) to examine memory
Stroop Color- Word Association Test(Stroop test)90 daysThis is a test used to find out the memory and executive function of patients.The test contains three small test.
Montreal Cognitive Assessment scale(MoCA)90 daysUsing this scale to measure cognitive function
Clinical Dementia Rating scale(CDR)90 daysUsing Clinical Dementia Rating scale(CDR) to measure the severity of dementia

Secondary

MeasureTime frameDescription
Activity of Daily Living Scale90 daysUsing this scale to measure daily living ability
National institute of health stroke scale90 daysUsing National institute of health stroke scale to measure the severity of stroke
Modified Rankin scale90 daysUsing Modified Rankin scale to measure the recovery of neurological function
Scores of Chinese medicine symptoms90 daysScores of Chinese medicine symptoms, which is a scale resulted from literature research, the argumentation of experts and clinical observation,contain 23 items of the core symptoms of cognitive impairment. And the scale is used to measure the changes of symptoms of Chinese medicine before and after treatment.

Other

MeasureTime frameDescription
whole blood cell test90 daysblood routine test
kidney function90 daystest the blood to detect the kidney function,such as blood urea nitrogen(BUN),creatinine (CRE),Uric acid(UA)
routine stool test90 daysexamine stool of the patients
homocysteine90 daysdetect the homocysteine in the blood
electrocardiogram90 dayselectrocardiograms are given before the experiment and on the 90th day of the experiment to test the condition of the patients' heart.
Liver function90 daystest the blood to detect the liver function,such as alanine aminotransferase(ALT) ,aspartate aminotransferase(AST),total bilirubin (TBIL), γ-glutamyl transferase(γ-GT).
routine urine test90 daysroutine urine test

Countries

China

Contacts

Primary ContactYunling Zhang, PhD,MD
yunlingzhang2004@126.com+86 10 6768963
Backup ContactYunling Zhang, PhD,MD
yunlingzhang2004@126.com+86 10 67689634

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026